Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
  • A61K31/724—Cyclodextrins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/40—Cyclodextrins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
  • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
  • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
  • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
  • C08L5/16—Cyclodextrin; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
  • A61K9/0051—Ocular inserts or implants

Definitions

• the present disclosure relates generally to compositions and methods for treating eye diseases (e.g ., retinopathies), and more particularly, eye diseases associated with retinal cell lipofuscin accumulation.
• eye diseases e.g ., retinopathies
• eye diseases associated with retinal cell lipofuscin accumulation e.g ., retinopathies
• Lipofuscin is a fine yellow-brown pigment composed of indigestible material that is believed to be remnants after lysosomal digestion. Lipofuscin is mostly composed of dimers of retinaldehydes known as lipid bisretinoids, and small amounts of carbohydrates, oxidized proteins and metals. Accumulation of lipofuscin in retinal cells causes retinal toxicity, which is associated with conditions like macular degeneration, a degenerative disease of the eye, and Stargardt disease.
• the present technology provides a method for preventing or treating an eye disease associated with retinal cell lipofuscin accumulation without impairing visual acuity in a subject in need thereof comprising administering to the subject an effective amount of sulfobutyl ether b-Cyclodextrin (SBE-pCD) or a pharmaceutically acceptable salt thereof.
• SBE-pCD sulfobutyl ether b-Cyclodextrin
• the eye disease associated with retinal cell lipofuscin accumulation may be selected from the group consisting of Stargardt disease (STGD), retinitis pigmentosa (RP), Age- Related Macular Degeneration (AMD), Best disease (BD), and cone-rod dystrophy.
• the eye disease is genetic, non-genetic, or associated with aging.
• the present technology provides a method for preventing or treating retinal cell lipofuscin accumulation without impairing visual acuity in a subject in need thereof comprising administering to the subject an effective amount of sulfobutyl ether b-Cyclodextrin (SBE-pCD) or a pharmaceutically acceptable salt thereof.
• SBE-pCD sulfobutyl ether b-Cyclodextrin
• administering prevents exacerbation of lipofuscin-associated retinal damage in the subject.
• Also disclosed herein are methods for reducing lipofuscin accumulation in retinal pigment epithelium cells comprising contacting the retinal pigment epithelium cells with an effective amount of sulfobutyl ether b-Cyclodextrin (SBE ⁇ CD) or a pharmaceutically acceptable salt thereof.
• SBE ⁇ CD sulfobutyl ether b-Cyclodextrin
• the SBE ⁇ CD or pharmaceutically acceptable salt thereof is configured to localize to retinal pigment epithelium cells.
• the SBE ⁇ CD or pharmaceutically acceptable salt thereof is configured to complex with lipofuscin bisretinoid lipids in the retinal pigment epithelium cells.
• the lipofuscin bisretinoid lipids may be N-retinylidene-N- retinylethanolamine (A2E), an A2E isomer, an oxidized derivative of A2E, or all-trans-retinal dimers.
• administering blocks, mitigates, or reverses accumulation of lipofuscin in retinal pigment epithelium cells.
• the SBE- bq ⁇ or pharmaceutically acceptable salt thereof is coupled to an agent that targets retinal pigment epithelium cells.
• the agent targets endosomes or lysosomes in the retinal pigment epithelium cells, such as mannose 6-phosphate.
• the XBE-bO ⁇ or pharmaceutically acceptable salt thereof is coupled to a fluorophore.
• fluorophores examples include, but are not limited to fluorescein, rhodamine, Oregon green, eosin, Texas Red, cyanine, streptocyanines, hemi cyanines, closed chain cyanines, phycocyanins, allophycocyanins, indocarbocyanines, oxacarbocyanines, thiacarbocyanines, merocyanins, and phthalocyanines, naphthalene derivatives ( e.g ., dansyl and prodan derivatives), coumarin and its derivatives, oxadiazole and its derivatives (e.g., pyridyloxazoles,
• nitrobenzoxadiazoles and benzoxadiazoles
• pyrene and its derivatives e.g., oxazine and its derivatives (e.g., Nile Red, Nile Blue, and cresyl violet), acridine derivatives (e.g., proflavin, acridine orange, and acridine yellow), arylmethine derivatives (e.g, auramine, crystal violet, and malachite green), and tetrapyrrole derivatives (e.g, porphyrins and bilirubins).
• oxazine and its derivatives e.g., Nile Red, Nile Blue, and cresyl violet
• acridine derivatives e.g., proflavin, acridine orange, and acridine yellow
• arylmethine derivatives e.g, auramine, crystal violet, and malachite green
• tetrapyrrole derivatives
• the SBE-pCD or pharmaceutically acceptable salt thereof is administered via topical, intravitreous, intraocular, subretinal, or subscleral administration.
• subscleral administration is achieved by implanting a slow-release subscleral implant in the subject.
• Figures 1A-1B show the structural formulae of the compositions of the present technology.
• Figure 1A shows the general formula for b (beta)-Cyclodextrins, which contain seven substituted glucopyranoside units. Substitutions are indicated by the symbol R.
• Figure IB shows the identities of the substituents in (i) Methyl beta-Cyclodextrin ( MpCD or MBCD); (ii) 2-hydroxypropyl beta-Cyclodextrin (HPpC’D); and (iii) Sulfobutyl ether b- Cyclodextrin (bBEbO ⁇ ).
• Figure 2 shows the removal of LB using the different cyclodextrins of the present technology at a dose of 4mM.
• Human RPE cultured cells were pre-loaded with lipofuscin by incubating them with 5 mM A2E overnight. Cells were washed and left untreated or treated with 4mM of a cyclodextrin compound (indicated on the X-axis). At 24 hrs., cells were harvested with trypsin, pelleted down and lysed in 2%Triton-buffer. A2E content was assessed by fluorescence at 430 nm and cell number was obtained by
• Figure 3A shows the dose-dependent removal of LB with methyl b- Cyclodextrin in the millimolar range.
• Epithelial cells loaded with A2E were treated with the indicated doses of methyl b-Cyclodextrin for 24 hours.
• untreated epithelial cells, which were not preloaded with A2E were treated with the indicated doses of methyl b- Cyclodextrin for 24 hours.
• A2E content per cell at the end of the incubation period was plotted as a function of the dose of methyl b-Cyclodextrin.
• Figure 3B shows removal of LB with methyl b-Cyclodextrin.
• Epithelial cells loaded with A2E were treated with methyl b-Cyclodextrin for 24 hours.
• fluorescence of A2E inside the cells was monitored by fluorescence microscopy at 100X magnification. Cells were stained with Hoechst stain to visualize nuclei of cells that contained A2E.
• Left column shows lipofuscin LB accumulation in an untreated control (A2E-Untreated), as shown by fluorescence for LB (turquoise, arrows) and nucleus (blue, arrow heads).
• Right column shows LB accumulation (turquoise, arrows) and nucleus (blue, arrow heads) after the treatment with methyl b-Cyclodextrin.
• Figures 4A-4B show the removal of LB with methyl b-Cyclodextrin as determined by fluorescence microscopy. Epithelial cells loaded with A2E were treated with methyl b-Cyclodextrin for 24 hours. Cells were stained with Hoechst stain to visualize nuclei. Fluorescence of A2E inside the cells (unextracted cells) was monitored by fluorescence microscopy at 100X magnification.
• Figure 4A shows LB-rich lipofuscin accumulation in an untreated control (A2E-Untreated), as shown by fluorescence for LB and nucleus.
• Figure 4B shows LB expelled from cells after treatment with 4 mM MbE ⁇ for 24 hrs.
• FIG. 5A shows the assays used to identify agents that remove lipofuscin in retinal cells.
• Cells were plated into 96 well plates at 1 x 10 5 cells per well. After 48 hrs in DMEM-10% media, the media was replaced with DMEM-10% media either with or without a test agent in a 24 hr removal assay.
• Figure 5B plots the correlation between picomoles of A2E per cell and fluorescence of known amounts of an A2E standard.
• A2E-specific fluorescence values fluorescence of lysates from cells pre-loaded with A2E minus fluorescence of corresponding lysates from control cells with no A2E loaded
• calibration curves generated by plotting fluorescence (430nm ex./600nm em) versus known amounts of an A2E standard dissolved in IX A2E-solubilizing buffers.
• composition of the A2E-solubilizing buffer was optimized to eliminate solvatochromic interferences with cyclodextrins that could disturb the calculations of the amount of A2E, using fluorescence.
• Figure 5C shows that under the conditions described in Figure 5B, the fluorescence of A2E is not affected by cyclodextrin complexation and that the fluorescence readout reflects the true A2E amounts.
• Figure 6 shows images of LB removal with methyl b-Cyclodextrin, 2-Hydroxy Propyl b-Cyclodextrin, and Sulfo Butyl Ether b-Cydodextrin.
• Untreated A2E-loaded RPE cultures served as negative controls.
• A2E-loaded RPE cultures were treated with 7.5 mM of the indicated b-Cyclodextrin compound for 48 hrs. For each cyclodextrin, three separate lots were tested.
• Lipofuscin (yellow) is visualized by fluorescence microscopy (488nm/600nm) using low magnification (10X) objective to capture a large number of cells.
• Figure 7 shows examples of the stoichiometric distribution of A2E at the end of the treatment with b-Cyclodextrins.
• Epithelial cells pre-loaded with A2E were treated in serum free media with 12.5 mM of the indicated b-Cyclodextrins for 4 hrs.
• A2E content in cell lysates and supernatants were determined by fluorescence assay as described in Figure 5A. As shown in Figure 7, the majority of A2E disappearing from the cells appeared in the supernatant.
• Figure 8 shows that b-Cyclodextrins exert a dose-dependent LB removal effect.
• Epithelial cells loaded with A2E were treated with the indicated doses of b- Cyclodextrins for 48 hours.
• untreated RPE cells, which were not preloaded with A2E were treated with the indicated doses of b-Cyclodextrins for 48 hours.
• A2E-specific fluorescence (ASF) for each drug concentration was calculated by subtracting the fluorescence of the control lysates from the fluorescence in the A2E-loaded cells lysate treated with the same cyclodextrin dose.
• ASF was interpolated in an A2E standard curve to convert to picomoles. Percentage of A2E-content per cell was plotted as a function of the dose of b-Cyclodextrin.
• Figure 9 shows the quantification of in vivo removal by methyl b- Cyclodextrin (M-bO ⁇ ), 2-Hydroxy Propyl b-Cyclodextrin (HR-bO ⁇ ), and Sulfo Butyl Ether b-Cydodextrin (SEB ⁇ CD).
• DKO double mutation
• FIGS 10A-10B show that the removal of LB with SEB ⁇ CD did not impair visual acuity.
• spatial frequency (SF) tests (a measure of visual acuity) were performed.
• SF was assessed by OptoMotry (Prusky GT, et al. (2004) Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system.
• FIG 11A shows that treatment with Sulfo Butyl Ether b-Cyclodextrin (SBE-BCD) does not compromise the integrity of the photoreceptor layer (ONL).
• SBE-BCD Sulfo Butyl Ether b-Cyclodextrin
• Figure 11B shows that the retinas of control and Sulfo Butyl Ether b- Cyclodextrin (SBE-BCD) treated animals were intact following treatment. Stitched images were created using ZEN Blue (Zeiss) from individual fields obtained by color microscopy of hematoxylin and eosin stained paraffin-embedded cross sections of retinas from mice treated with lpl vehicle or Sulfo Butyl b-Cyclodextrin.
• ZEN Blue Zeiss
• Toxic lipid bisretinoids (LB), the main components of eye lipofuscin, accumulate with age in the lysosomes of Retinal Pigment Epithelium, a major retinal support cell responsible for the survival of photoreceptors, the light sensing cells.
• LB accumulation in RPE is enhanced in human genetic diseases such as Stargardt disease (STGD), ABCA4- related forms of cone-rod dystrophy (CRD), and retinitis pigmentosa (RP).
• STGD Stargardt disease
• CCD ABCA4- related forms of cone-rod dystrophy
• RP retinitis pigmentosa
• accumulation is believed to be toxic for RPE and to be a key aspect of the etiology of these diseases. Furthermore, accumulation of LB with age is a risk factor for Age- Related Macular Degeneration (AMD), an incurable disease that affects 25% of the senior population.
• AMD Age- Related Macular Degeneration
• agents that remove cellular LB have potential to fulfill an unmet need in the treatment of human blinding diseases.
• Cyclodextrins are cyclic oligosaccharides containing glucose subunits j oined by a- 1,4 glycosidic bonds. Cyclodextrins are produced from starch by enzymatic conversion, and are classified as a-cyclodextrin, as containing six glucose subunits, b-Cyclodextrin, as containing seven glucose subunits, and g-cyclodextrin, as containing 8 glucose subunits a-, b-, as well as g-cyclodextrins are all generally recognized as safe by the Food and Drug Administration (FDA), and are commonly used in food, pharmaceutical, drug delivery, and chemical industries, as well as agriculture and environmental engineering.
• FDA Food and Drug Administration
• methyl beta-Cyclodextrin (M ⁇ CD) and 2-hydroxypropyl beta-Cyclodextrin (HP- bCD) are considered safe.
• HP ⁇ CD has received END status from FDA for the treatment of Niemann-Pick Type Cl Disease.
• the present disclosure is based, in part, on the discovery that not all cyclodextrins are effective in promoting in vivo removal of lipofuscin from epithelial cells. It was unexpectedly discovered that (i) Methyl beta-Cyclodextrin (MbCD); (ii) 2-hydroxypropyl beta-Cyclodextrin (EE ⁇ CD); and (iii) Sulfobutyl ether b-Cyclodextrin (SBEbCD) are effective in promoting LB removal, whereas other derivatives such as alpha-cyclodextrin, gamma-cyclodextrin, 2,6-di-0-methyl ⁇ -Cyclodextrin (Heptakis 2,6-di-O-methyl) and 2,3,6- tri-O-methyl ⁇ -Cyclodextrin (Heptakis 2,3,6-tri-O-methyl) fail to effectively remove cellular LB.
• MbCD Methyl beta-Cy
• both methyl b-Cyclodextrin and hydroxy propyl b-Cyclodextrin produced significant impairment of visual acuity in vivo, while Sulfo Butyl Ether b-Cyclodextrin did not impair visual acuity.
• the present disclosure provides methods for treating a subject suffering from an eye disease associated with retinal cell lipofuscin accumulation.
• Conditions and diseases treatable by the method described herein include any ophthalmologic or retinal disorder, condition, or disease directly or indirectly caused by the accumulation of lipofuscin in retinal pigment epithelium (RPE) cells, which may be genetic or non-genetic, such as age-related macular degeneration (AMD), Stargardt disease (SD), Best disease (BD), retinitis pigmentosa, and cone-rod dystrophy.
• RPE retinal pigment epithelium
• the term“about” in reference to a number is generally taken to include numbers that fall within a range of 1%, 5%, or 10% in either direction (greater than or less than) of the number unless otherwise stated or otherwise evident from the context (except where such number would be less than 0% or exceed 100% of a possible value).
• the“administration” of an agent or drug to a subject includes any route of introducing or delivering to a subject a compound to perform its intended function. Administration can be carried out by any suitable route, including but not limited to, orally, intranasally, parenterally (intravenously, intramuscularly, intraperitoneally, or
• Administration includes self administration and the administration by another.
• biological sample means sample material derived from living cells.
• Biological samples may include tissues, cells, protein or membrane extracts of cells, and biological fluids (e.g ., ascites fluid or cerebrospinal fluid (CSF)) isolated from a subject, as well as tissues, cells and fluids present within a subject.
• biological fluids e.g ., ascites fluid or cerebrospinal fluid (CSF)
• Biological samples of the present technology include, but are not limited to, samples taken from eye, breast tissue, renal tissue, the uterine cervix, the endometrium, the head or neck, the gallbladder, parotid tissue, the prostate, the brain, the pituitary gland, kidney tissue, muscle, the esophagus, the stomach, the small intestine, the colon, the liver, the spleen, the pancreas, thyroid tissue, heart tissue, lung tissue, the bladder, adipose tissue, lymph node tissue, the uterus, ovarian tissue, adrenal tissue, testis tissue, the tonsils, thymus, blood, hair, buccal, skin, serum, plasma, CSF, semen, prostate fluid, seminal fluid, urine, feces, sweat, saliva, sputum, mucus, bone marrow, lymph, and tears.
• Biological samples can also be obtained from biopsies of internal organs.
• Biological samples can be obtained from subjects for diagnosis or research or can be obtained from non-diseased individuals, as controls or for basic research. Samples may be obtained by standard methods including, e.g., venous puncture and surgical biopsy. In certain
• the biological sample is a tissue sample obtained by needle biopsy.
• a“control” is an alternative sample used in an experiment for comparison purpose.
• a control can be“positive” or“negative.”
• a positive control a compound or composition known to exhibit the desired therapeutic effect
• a negative control a subject or a sample that does not receive the therapy or receives a placebo
• the term“effective amount” refers to a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect, e.g., an amount which results in the prevention of, or a decrease in a disease or condition described herein or one or more signs or symptoms associated with a disease or condition described herein.
• the amount of a composition administered to the subject will vary depending on the composition, the degree, type, and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
• the compositions can also be administered in combination with one or more additional therapeutic compounds.
• the therapeutic compositions may be administered to a subject having one or more signs or symptoms of a disease or condition described herein.
• a“therapeutically effective amount” of a composition refers to composition levels in which the physiological effects of a disease or condition are ameliorated or eliminated.
• a therapeutically effective amount can be given in one or more administrations.
• the terms“individual”,“patient”, or“subject” can be an individual organism, a vertebrate, a mammal, or a human. In some embodiments, the individual, patient or subject is a human.
• the term“pharmaceutically-acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal compounds, isotonic and absorption delaying compounds, and the like, compatible with pharmaceutical administration.
• Pharmaceutically-acceptable carriers and their formulations are known to one skilled in the art and are described, for example, in Remington's Pharmaceutical Sciences (20th edition, ed. A. Gennaro, 2000, Lippincott, Williams & Wilkins, Philadelphia, Pa.).
• Examples of pharmaceutically-acceptable carriers include a liquid or solid filler, diluent, excipient, manufacturing aid (e.g lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, useful for introducing the active agent into the body.
• manufacturing aid e.g lubricant, talc magnesium, calcium or zinc stearate, or steric acid
• solvent encapsulating material useful for introducing the active agent into the body.
• “prevention,”“prevent,” or“preventing” of a disorder or condition refers to one or more compounds that, in a statistical sample, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset of one or more symptoms of the disorder or condition relative to the untreated control sample.
• the term“separate” therapeutic use refers to an administration of at least two active ingredients at the same time or at substantially the same time by different routes.
• the term“sequential” therapeutic use refers to administration of at least two active ingredients at different times, the administration route being identical or different. More particularly, sequential use refers to the whole administration of one of the active ingredients before administration of the other or others commences. It is thus possible to administer one of the active ingredients over several minutes, hours, or days before administering the other active ingredient or ingredients. There is no simultaneous treatment in this case.
• the term“simultaneous” therapeutic use refers to the administration of at least two active ingredients by the same route and at the same time or at substantially the same time.
• Treating” or“treatment” as used herein covers the treatment of a disease or disorder described herein, in a subject, such as a human, and includes: (i) inhibiting a disease or disorder, i.e., arresting its development; (ii) relieving a disease or disorder, i.e., causing regression of the disorder; (iii) slowing progression of the disorder; and/or (iv) inhibiting, relieving, or slowing progression of one or more symptoms of the disease or disorder.
• treatment means that the symptoms associated with the disease are, e.g., alleviated, reduced, cured, or placed in a state of remission.
• the various modes of treatment of disorders as described herein are intended to mean“substantial,” which includes total but also less than total treatment, and wherein some biologically or medically relevant result is achieved.
• the treatment may be a continuous prolonged treatment for a chronic disease or a single, or few time administrations for the treatment of an acute condition.
• Macular conditions that exhibit lipofuscin accumulation include Best macular dystrophy, Stargardt disease/ Fundus flavimaculatus, ABCA4-related retinitis pigmentosa, ABCA4-related rod-cone dystrophy, and age-related macular degeneration (AMD).
• RPE retinal pigment epithelial
• ALD age-related macular degeneration
• Lipofuscin is resistant to lysosomal enzyme degradation, and is believed to be the remnant of lysosomal digestion.
• Lipofuscin in the eye contains mostly lipid bisretinoids A2E, isoA2E, and all-trans-retinal dimer- phosphatidylethanolamine.
• Lipofuscin also contains small amounts of peptides featuring oxidative modifications, like nitrotyrosine, generated from reactive nitrogen oxide species and carboxyethylpyrrole, and iso[4]levuglandin E2 adducts generated from reactive lipid fragments, etc. See, e.g., Ng K-P, et al. (2008) Retinal Pigment Epithelium Lipofuscin Proteomics. Mol Cell Proteomics 7(7): 1397- 1405; Ben-Shabat S, et al. Fluorescent pigments of the retinal pigment epithelium and age-related macular degeneration. BioorgMed Chem Lett 11(12): 1533-40 (2001).
• Lipofuscin accumulates with age and can increase due to genetic predispositions and certain underlying conditions. See Molday RS, Zhong M, Quazi F, The role of the photoreceptor ABC transporter ABCA4 in lipid transport and Stargardt macular
• Pharmacological therapies targeting LB deposits that are currently under development include strategies that block de novo formation of LB, and strategies for removing LB.
• the strategies that block de novo formation of LB include administration of fenretinide, emixustat hydrochloride, deuterated vitamin A, and aldehyde traps.
• the disadvantage of such strategies is that although they may prevent de novo formation of LBs, they cannot reduce pre-existing LB deposits. Therefore, strategies that block de novo formation of LB would provide little or no benefit for patients with established clinical symptoms.
• Strategies for removing LB include administration of soraprazan, and enzymatic degradation of LB. None of these existing strategies have progressed enough to confer a clinical benefit on patients.
• Oral emixustat hydrochloride (Acucela Inc) is a synthetic non-retinoid reversible inhibitor of the RPE65 enzyme, which converts all-trans-retinyl to 11-cis-retinal, promoting the endogenous synthesis of the latter.
• the results from the phase 2b/3 SEATTLE study did not show any significant difference in retinal degenerative rate or visual acuity changes. Emixustant also caused significant night blindness that limits it use.
• emixustat has no effect on pre-existing LB deposits.
• Oral deuterated vitamin A is vitamin A modified by replacing hydrogen with deuterium, a safe, non-radioactive isotope.
• Deuterated vitamin A has lower tendency to spontaneously dimerize into LB.
• Long-term, oral administration of ALK-001 to ABCA4-/- reduced the accumulation of lipofuscin and A2E by 70% and 80%, respectively.
• Assessment of the retina electric response to light signals revealed that ALK-001 treatment prevented the gradual loss of visual function observed in the ABCA4-/- mouse model.
• Safety phase-1 clinical trials have been completed (NCT02230228) and Phase 2 multicenter clinical trial for the treatment of STGD1 (NCT02402660) are ongoing. Given that ALK-001 blocks formation of lipofuscin, it is uncertain as to whether it would have an effect on pre-existing LB deposits in AMD patients.
• Oral aldehyde traps (VM200, Vision Medicines) constitute new drugs that react with retinaldehydes forming reversible Schiff bases and thus reducing the available levels of free aldehydes with cellular amine groups. See Maeda A, et al. (2012) Primary amines protect against retinal degeneration in mouse models of retinopathies. Nat Chem Biol 8(2): 170-8.
• HRP Horseradish peroxidase
• compositions that sequester and eliminate LB deposits from retinal cells e.g., methyl beta-Cyclodextrin (MpCD), 2-hydroxypropyl beta- Cyclodextrin (HPPCD), sulfobutyl ether b-Cyclodextrin (SBEpCD), and any
• the present disclosure provides methods of preventing or treating a subject suffering from an eye disease associated with retinal cell lipofuscin accumulation, the method comprising administering to the subject a therapeutically effective amount of a substituted b-Cyclodextrin, wherein the substituted b-Cyclodextrin comprises a randomly substituted beta-Cyclodextrin with a degree of substitution (DS) between 4 and 14.5.
• a degree of substitution DS
• the present technology provides a method for preventing or treating an eye disease associated with retinal cell lipofuscin accumulation without impairing visual acuity in a subject in need thereof comprising administering to the subject an effective amount of sulfobutyl ether b-Cyclodextrin (SBE ⁇ CD) or a pharmaceutically acceptable salt thereof.
• SBE ⁇ CD sulfobutyl ether b-Cyclodextrin
• the eye disease associated with retinal cell lipofuscin accumulation may be selected from the group consisting of Stargardt disease (STGD), retinitis pigmentosa (RP), Age- Related Macular Degeneration (AMD), Best disease (BD), and cone-rod dystrophy.
• Conditions and diseases treatable by the methods described herein include any one or more of
• RPE retinal pigment epithelium
• AMD age-related macular degeneration
• BD Best disease
• BD retinitis pigmentosa
• cone-rod dystrophy a genetic or non-genetic, such as age-related macular degeneration (AMD), Stargardt disease, Best disease (BD), retinitis pigmentosa, and cone-rod dystrophy.
• AMD age-related macular degeneration
• BD Best disease
• retinitis pigmentosa retinitis pigmentosa
• cone-rod dystrophy cone-rod dystrophy
• the eye disease is genetic, non- genetic, or associated with aging.
• the present technology provides a method for preventing or treating retinal cell lipofuscin accumulation without impairing visual acuity in a subject in need thereof comprising administering to the subject an effective amount of sulfobutyl ether b-Cyclodextrin (SBE-flCD) or a pharmaceutically acceptable salt thereof.
• SBE-flCD sulfobutyl ether b-Cyclodextrin
• administering prevents exacerbation of lipofuscin-associated retinal damage in the subject.
• Also disclosed herein are methods for reducing lipofuscin accumulation in retinal pigment epithelium cells comprising contacting the retinal pigment epithelium cells with an effective amount of sulfobutyl ether b-Cyclodextrin (SBE ⁇ CD) or a pharmaceutically acceptable salt thereof.
• SBE ⁇ CD sulfobutyl ether b-Cyclodextrin
• the treatment considered herein has the effect of stopping, mitigating, or reversing the accumulation erf lipofuscin bisretinoid lipid in RPE cells, and likewise, stopping, mitigating, or reversing the lipofuscin-associated damage or associated disease or condition.
• the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof are configured to complex and remove lipofuscin bisretinoid lipid in RPE cells.
• the one or more b- cyclodextrins or pharmaceutically acceptable salts thereof possess a cavity ( binding pocket) suitable for accepting at least one lipofuscin bisretinoid lipid molecule as a partner
• the result is a complex between the p-cycSodextrin(s) and lipofuscin bisretinoid lipid molecule.
• the interaction between the b-cyclodextrinis) and lipofuscin bisretinoid lipid molecule is generally of a nan-covalent nature, such as by hydrogen-bonding and/or van der Waals (dispersion) forces.
• the lipofuscin bisretinoid lipid is generally A2E, an A2E isomer, an oxidized derivative of A2E, A2-dihydropyridine-phosphatidy3ethanoIamine, or an all-trans retinal dimer
• pharmaceutically acceptable salt means a salt prepared from a base or an acid which is acceptable for administration to a patient, such as a mammal (e.g., salts having acceptable mammalian safety for a given dosage regime). However, it is understood that the salts are not required to be pharmaceutically acceptable salts, such as salts of intermediate compounds that are not intended for administration to a patient. Pharmaceutically acceptable salts can be derived from pharmaceutically acceptable inorganic or organic bases and from pharmaceutically acceptable inorganic or organic acids.
• b- cyclodextrins of the present technology contains both a basic moiety, such as an amine, pyridine or imidazole, and an acidic moiety such as a carboxylic acid or tetrazole, zwitterions may be formed and are included within the term "salt" as used herein.
• the one or more b-cyclodextrins may contain one or more basic functional groups, such as amino or alkylamino, and thereby, can form pharmaceutically- acceptable salts by reaction with a pharmaceutically-acceptable acid.
• These salts can be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting a purified compound of the present technology in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed during subsequent purification.
• the one or more b-cyclodextrins may contain one or more acidic functional groups, and thereby, can form pharmaceutically-acceptable salts by reaction with a pharmaceutically-acceptable base.
• salts can likewise be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting the purified compound in its free acid form (e.g ., hydroxyl or carboxyl) with a suitable base, and isolating the salt thus formed during subsequent purification.
• free acid form e.g ., hydroxyl or carboxyl
• Salts derived from pharmaceutically acceptable inorganic bases include ammonium, aluminum, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, and zinc salts, and the like.
• Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, ethylamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, diethanolamine,
• ethylenediamine N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperadine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine,
• Salts derived from pharmaceutically acceptable inorganic acids include salts of boric, carbonic, hydrohalic (hydrobromic, hydrochloric, hydrofluoric or hydroiodic), nitric, phosphoric, sulfamic and sulfuric acids.
• Salts derived from pharmaceutically acceptable organic acids include salts of aliphatic hydroxyl acids (e.g., citric, gluconic, glycolic, lactic, lactobionic, malic, and tartaric acids), aliphatic
• monocarboxylic acids e.g., acetic, butyric, formic, propionic and trifluoroacetic acids
• amino acids e.g, aspartic and glutamic acids
• aromatic carboxylic acids e.g., benzoic, 2- acetoxybenzoic, p-chlorobenzoic, diphenylacetic, gentisic, hippuric, and triphenylacetic acids
• aromatic hydroxyl acids e.g ., o-hydroxybenzoic, p-hydroxybenzoic, 1- hydroxynaphthalene-2-carboxylic and 3-hydroxynaphthalene-2-carboxylic acids
• dicarboxylic acids e.g., fumaric, maleic, oxalic and succinic acids
• glucuronic mandelic, mucic, nicotinic, orotic, pamoic, pantothenic
• sulfonic acids e.g., benzenesulfonic, camp
• ethanedisulfonic citric, ascorbic, maleic, oxalic, fumaric, phenylacetic, isothionic, succinic, tartaric, glutamic, salicylic, sulfanilic, napthylic, lactobionic, gluconic, laurylsulfonic acids, and the like.
• administration of the effective amount of the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof prevent exacerbation of lipofuscin-associated retinal damage in the subject.
• administration of the effective amount of the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof block, mitigate, or reverse accumulation of lipofuscin in retinal pigment epithelium cells.
• administration of the effective amount of the one or more b- cyclodextrins or pharmaceutically acceptable salts thereof prevent, slow the onset, or lessen the severity of lipofuscin-associated damage or a disease or condition directly or indirectly associated with lipofuscin-associated damage or lipofuscin accumulation in RPE cells of the subject.
• the subject can be of any gender (e.g., male or female), and/or can also be any age, such as elderly (generally, at least or above 60, 70, or 80 years of age), elderly-to-adult transition age subjects, adults, adult-to-pre-adult transition age subjects, and pre-adults, including adolescents (e.g., 13 and up to 16, 17, 18, or 19 years of age), children (generally, under 13 or before the onset of puberty), and infants.
• the subject can also be of any ethnic population or genotype. Some examples of human ethnic populations include Caucasians, Asians, Hispanics, Africans, African Americans, Native Americans, Semites, and Pacific Islanders.
• the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof are configured to localize to RPE cells.
• the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof are configured to complex with lipofuscin bisretinoid lipids in the RPE cells.
• the complex can be considered an organized chemical entity resulting from the association of two or more components held together by non- covalent intermolecular forces.
• the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof localize to RPE cells by being administered directly at, into, or in the adjacent vicinity of RPE cells, such as by injection or implantation.
• the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof localize to RPE cells by coupling the one or more b-cyclodextrins or
• the cell-targeting agent i.e.,“targeting agent” is any chemical entity that has the ability to bind to (i.e.,“target”) a RPE cell.
• the cell targeting agent may target any part of the RPE cell, e.g., cell membrane, organelle (e.g., lysosome or endosome), or cytoplasm.
• the cell-targeting agent targets a component of a RPE cell in a selective manner.
• the cell-targeting agent can, for example, selectively target certain components of cells over other types of cellular components.
• the targeting agent targets cellular components non-selectively, e.g., by targeting cellular components found in most or all cells.
• the targeting agent can be, or include, for example, a peptide, dipeptide, tripeptide (e.g., glutathione), tetrapeptide, pentapeptide, hexapeptide, higher oligopeptide, protein, monosaccharide, disaccharide, trisaccharide, tetrasaccharide, higher oligosaccharide, polysaccharide (e.g., a carbohydrate), nucleobase, nucleoside (e.g., adenosine, cytidine, uridine, guanosine, thymidine, inosine, and S-Adenosyl methionine), nucleotide (i.e., mono-, di-, or tri-phosphate forms), dinucleotide, trinucleotide,
• a peptide, dipeptide, tripeptide e.g., glutathione
• tetrapeptide pent
• tetranucleotide higher oligonucleotide, nucleic acid, cofactor (e.g., TPP, FAD, NAD, coenzyme A, biotin, lipoamide, metal ions (e.g., Mg 2+ ), metal-containing clusters (e.g., the iron-sulfur clusters), or a non-biological (i.e., synthetic) targeting group.
• cofactor e.g., TPP, FAD, NAD, coenzyme A
• biotin lipoamide
• metal ions e.g., Mg 2+
• metal-containing clusters e.g., the iron-sulfur clusters
• non-biological targeting group i.e., synthetic targeting group.
• proteins include enzymes, hormones, antibodies (e.g., monoclonal antibodies), lectins, and steroids.
• Antibodies for use as targeting agents are generally specific for one or more cell surface antigens.
• the antigen is a receptor.
• the antibody can be a whole antibody, or alternatively, a fragment of an antibody that retains the recognition portion (i.e., hypervariable region) of the antibody.
• Some examples of antibody fragments include Fab, Fc, and F(ab')2.
• the antibody or antibody fragment can be chemically reduced to derivatize the antibody or antibody fragment with sulfhydryl groups.
• the targeting agent is a ligand of an internalized receptor of the target cell.
• the targeting agent can be a targeting signal for acid hydrolase precursor proteins that transport various materials to lysosomes.
• One such targeting agent of particular interest is mannose-6-phosphate (M6P), which is recognized by mannose 6- phosphate receptor (MPR) proteins in the trans-Golgi. Endosomes are known to be involved in transporting M6P-labeled substances to lysosomes.
• the targeting agent is a peptide containing an RGD sequence, or variants thereof, that bind RGD receptors on the surface of many types of cells.
• Other targeting agents include, for example, transferrin, insulin, amylin, and the like.
• Receptor internalization may be used to facilitate intracellular delivery of the one or more b- cyclodextrins or pharmaceutically acceptable salts thereof described herein.
• one cell-targeting molecule or group, or several ( e.g ., two, three, or more) of the same type of cell -targeting molecule or group are attached to the one or more b- cyclodextrins or pharmaceutically acceptable salts thereof directly or via a linker.
• two or more different types of targeting molecules are attached to the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof directly or via a linker.
• a fluorophore may be attached to the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof.
• Incorporation of one or more fluorophores can have several purposes.
• one or more fluorophores are included in order to quantify cellular uptake and retention of the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof (e.g., by a fluorescence spectroscopic method).
• a“fluorophore” refers to any species with the ability to fluoresce (i.e., that possesses a fluorescent property).
• the fluorophore is an organic fluorophore.
• the organic fluorophore can be, for example, a charged (i.e., ionic) molecule (e.g., sulfonate or ammonium groups), uncharged (i.e., neutral) molecule, saturated molecule, unsaturated molecule, cyclic molecule, bicyclic molecule, tricyclic molecule, polycyclic molecule, acyclic molecule, aromatic molecule, and/or heterocyclic molecule (i.e., by being ring-substituted by one or more heteroatoms selected from, for example, nitrogen, oxygen and sulfur).
• a charged (i.e., ionic) molecule e.g., sulfonate or ammonium groups
• uncharged (i.e., neutral) molecule saturated molecule, unsaturated molecule, cyclic molecule, bicyclic molecule, tricyclic molecule, polycyclic molecule, acyclic molecule, aromatic molecule, and/or heterocyclic molecule (i.e
• the fluorophore contains one, two, three, or more carbon-carbon and/or carbon-nitrogen double and/or triple bonds.
• the fluorophore contains at least two ( e.g ., two, three, four, five, or more) conjugated double bonds aside from any aromatic group that may be in the fluorophore.
• the fluorophore is a fused polycyclic aromatic hydrocarbon (PAH) containing at least two, three, four, five, or six rings (e.g., naphthalene, pyrene, anthracene, chrysene, triphenylene, tetracene, azulene, and phenanthrene) wherein the PAH can be optionally ring-substituted or derivatized by one, two, three or more heteroatoms or heteroatom-containing groups.
• PAH fused polycyclic aromatic hydrocarbon
• the organic fluorophore is a xanthene derivative (e.g., fluorescein, rhodamine, Oregon green, eosin, and Texas Red), cyanine or its derivatives or subclasses (e.g., streptocyanines, hemicyanines, closed chain cyanines, phycocyanins, allophycocyanins, indocarbocyanines, oxacarbocyanines, thiacarbocyanines, merocyanins, and phthalocyanines), naphthalene derivatives (e.g, dansyl and prodan derivatives), coumarin and its derivatives, oxadiazole and its derivatives (e.g., pyridyloxazoles,
• cyanine or its derivatives or subclasses e.g., streptocyanines, hemicyanines, closed chain cyanines, phycocyanins, allophycocyanins, indocarbocyanines
• nitrobenzoxadiazoles and benzoxadiazoles
• pyrene and its derivatives e.g, oxazine and its derivatives (e.g, Nile Red, Nile Blue, and cresyl violet), acridine derivatives (e.g, proflavin, acridine orange, and acridine yellow), arylmethine derivatives (e.g., auramine, crystal violet, and malachite green), and tetrapyrrole derivatives (e.g., porphyrins and bilirubins).
• Some particular families of dyes considered herein are the Cy® family of dyes, the Alexa® family of dyes, the ATTO® family of dyes, and the Dy® family of dyes.
• the ATTO® dyes in particular, can have several structural motifs, including, coumarin-based, rhodamine-based, carbopyronin-based, and oxazine-based structural motifs.
• the fluorophore can be attached to the one or more b-cyclodextrins or
• a commercial mono-reactive fluorophore e.g, NHS-Cy5
• bis-reactive fluorophore e.g, bis-NHS-Cy5 or bis-maleimide-Cy5
• appropriate reactive groups e.g, amino, thiol, hydroxy, aldehydic, or ketonic groups.
• the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof can be administered by any route that permits contact with RPE cells.
• the administration can be, for example, ocular, parenteral (e.g ., subcutaneous, intramuscular, or intravenous), topical, transdermal, intravitreous, retro-orbital, subretinal, subscleral, oral, sublingual, or buccal modes of administration.
• Some of the foregoing exemplary modes of administration can be achieved by injection.
• injection is avoided by use of a slow-release implant in the vicinity of the retina (e.g., subscleral route) or by administering drops to the conjuctiva.
• the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof of the present technology may be administered locally, to the eyes of patients suffering from lipofuscin accumulation including Stargardt, carriers of ABCA4 defective genes, dry AMD or at risk for developing retinal degeneration due to the accumulation of lipid bisretinoids (lipofuscin).
• Local administration includes intravitreal, topical ocular, transdermal patch, subdermal, parenteral, intraocular, subconjunctival, or retrobulbar or subtenon' s injection, trans-scleral (including iontophoresis), posterior juxtascleral delivery, or slow release biodegradable polymers or liposomes.
• trans-scleral including iontophoresis
• posterior juxtascleral delivery or slow release biodegradable polymers or liposomes.
• the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof can also be delivered in ocular irrigating solutions. Concentrations may range from about 0.001 mM to about 100 mM, preferably about 0.01 mM to about 5 mM.
• the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof are administered, at least initially, at levels lower than that required in order to achieve a desired therapeutic effect, and the dose is gradually or suddenly increased until a desired effect is achieved.
• the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof are administered, at least initially, at levels higher than that required in order to accelerate a desired therapeutic effect, and the dose gradually or suddenly moderated until a desired effect is achieved.
• the selected dosage level will depend upon several factors, as determined by a medical practitioner. Some of these factors include the type of disease or condition being treated, the stage or severity of the condition or disease, the efficacy of the therapeutic compound being used and its bioavailability profile, as well as the specifics (e.g., genotype and phenotype) of the subject being treated, e.g., age, sex, weight, and overall condition.
• the dosage can be, for example, in the range of about 0.01, 0.1, 0.5, 1, 5, or 10 mg per kg of body weight per day to about 20,
• the dosage can disregard body weight, and can be in smaller amounts ( e.g ., 1-1000 pg per dose).
• the daily dose of the one or more b- cyclodextrins or pharmaceutically acceptable salts thereof is the lowest dose effective to produce a therapeutic effect.
• the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof are not administered in discrete dosages, but in a continuous mode, such as provided by a slow release implant or intravenous line.
• the present disclosure provides pharmaceutical compositions comprising a substituted b-Cyclodextrin, wherein the substituted substituted b-Cyclodextrin comprises a randomly substituted beta-Cyclodextrin with a degree of substitution (DS) between 4 and 14.5.
• the present disclosure provides pharmaceutical compositions comprising one or more cyclodextrins selected from the group consisting of methyl beta-Cyclodextrin (Mb ⁇ ), 2-hydroxypropyl beta-Cyclodextrin (HRbO ⁇ ), sulfobutyl ether b-Cyclodextrin (SBEbCD), and pharmaceutically acceptable salts thereof.
• the one or more b-cyclodextrins or pharmaceutically acceptable salts thereof may be formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents, known in the art.
• the pharmaceutical compositions of the present technology may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) sublingually; (5) ocularly; (6) transdermally;
• compositions of the present technology may contain one or more“pharmaceutically-acceptable carriers,” which as used herein, generally refers to a pharmaceutically-acceptable composition, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, useful for introducing the active agent into the body.
• a pharmaceutically-acceptable composition such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, useful for introducing the active agent into the body.
• manufacturing aid e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid
• solvent encapsulating material useful for introducing the active agent into the body.
• Each carrier must be“acceptable”
• aqueous and non-aqueous carriers examples include, for example, water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), vegetable oils (such as olive oil), and injectable organic esters (such as ethyl oleate), and suitable mixtures thereof.
• polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
• vegetable oils such as olive oil
• injectable organic esters such as ethyl oleate
• the formulations may include one or more of sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; alginic acid; buffering agents, such as magnesium hydroxide and aluminum hydroxide; pyrogen-free water; isotonic s
• sugars such as lacto
• auxiliary agents such as wetting agents, emulsifiers, lubricants (e.g ., sodium lauryl sulfate and magnesium stearate), coloring agents, release agents, coating agents, sweetening agents, flavoring agents, preservative agents, and antioxidants can also be included in the pharmaceutical composition.
• antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like; (2) oil- soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethyl enediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
• water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like
• oil- soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytolu
• the pharmaceutical formulation includes an excipient selected from, for example, celluloses, liposomes, micelle forming agents (e.g., bile acids), and polymeric carriers, e.g., polyesters and polyanhydrides.
• Suspensions in addition to the active compounds, may contain suspending agents, such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
• antibacterial and antifungal agents such as, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions.
• prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption, such as aluminum monostearate and gelatin.
• compositions of the present technology may be prepared by any of the methods known in the pharmaceutical arts.
• the amount of active ingredient that can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated and the particular mode of administration.
• the amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound that produces a therapeutic effect.
• the amount of active compound will be in the range of about 0.1 to 99 percent, more typically, about 5 to 70 percent, and more typically, about 10 to 30 percent.
• compositions of the present technology may be administered locally, to the eyes of patients suffering from lipofuscin accumulation including Stargardt, carriers of ABCA4 defective genes, dry AMD or at risk for developing retinal degeneration due to the accumulation of lipid bisretinoids (lipofuscin).
• lipofuscin lipid bisretinoids
• the one or more b-cyclodextrins of the present technology or pharmaceutically acceptable salts thereof can be incorporated into various types of ophthalmic formulations for delivery to the eye ( e.g ., topically,
• the one or more b-cyclodextrins of the present technology or pharmaceutically acceptable salts thereof may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, gelling agents, penetration enhancers, buffers, sodium chloride, and water to form aqueous, sterile ophthalmic suspensions or solutions or preformed gels or gels formed in situ.
• the substituted b -Cyclodextrin of the present technology e.g., methyl beta-Cyclodextrin (MbEO), 2-hydroxypropyl beta-Cyclodextrin (HRb ⁇ ), sulfobutyl ether b-Cyclodextrin (8BEb ⁇ ), and pharmaceutically acceptable salts thereof
• MbEO methyl beta-Cyclodextrin
• HRb ⁇ 2-hydroxypropyl beta-Cyclodextrin
• 8BEb ⁇ sulfobutyl ether b-Cyclodextrin
• pharmaceutically acceptable salts thereof is administered 1-10 times a day, once a day, twice, three, four, or more times a day, 1-3 times a day, 2-4 times a day, 3-6 times a day, 4-8 times a day or 5-10 times a day.
• the substituted b-Cyclodextrin e.g., methyl beta-Cyclodextrin (MbCD), 2- hydroxypropyl beta-Cyclodextrin (HRbEO), sulfobutyl ether b-Cyclodextrin (SBEbCD), and pharmaceutically acceptable salts thereof
• MbCD methyl beta-Cyclodextrin
• HRbEO 2- hydroxypropyl beta-Cyclodextrin
• SBEbCD sulfobutyl ether b-Cyclodextrin
• pharmaceutically acceptable salts thereof is administered every day, every other day, 2-3 times a week, or 3-6 times a week.
• the dose of the substituted b-Cyclodextrin can be, for example, in the range of about 0.01, 0.1, 0.5, 1, 5, 10, or 100 mg per kg of body weight per day to about 20, 50, 100, 500, or 1000 mg per kilogram of body weight. Particularly in
• the dosage administered can be independent of body weight, and can be in smaller amounts (e.g., 1-1000 pg per dose).
• the one or more b-cyclodextrins of the present technology or pharmaceutically acceptable salts thereof may be formulated as topical ophthalmic suspensions or solutions, with a pH of about 4 to 8.
• the one or more b-cyclodextrins of the present technology or pharmaceutically acceptable salts thereof will normally be contained in these formulations in an amount 0.001% to 5% by weight, or in an amount of 0.01% to 2% by weight.
• 1 to 2 drops of these formulations would be delivered to the surface of the eye 1 to 4 times per day according to the discretion of a skilled clinician.
• the pharmaceutical compositions of the present technology containing therapeutically effective amounts of at least one monomeric or polymeric cyclodextrins, are delivered intravitreally either through an injection (perhaps microspheres), an intravitreal device, or placed in the sub-Tenon space by injection, gel, or implant, or by other methods discussed above.
• the therapeutically effective amount of the one or more b-cyclodextrins of the present technology or pharmaceutically acceptable salts thereof in the composition might be about 18-44 mM, of a concentration of about 20-50%.
• a therapeutically effective amount of the one or more b-cyclodextrins of the present technology or pharmaceutically acceptable salts thereof is about 20-80%.
• the therapeutically effective amount of the one or more b-cyclodextrins of the present technology or pharmaceutically acceptable salts thereof is administered in the form of a mini-tablet, each weighing from about 1 mg to about 40 mg, or about 5 mg. From one to twenty such mini-tablets may be injected [dry] into the sub- Tenon space through a trochar in one dose, so that a total single dose of 50-100 mg [44-88 mM] is injected.
• the substituted b -Cyclodextrin e.g., methyl beta-Cyclodextrin (MflCD), 2-hydroxypropyl beta-Cyclodextrin (HI ⁇ CD), sulfobutyl ether b-Cyclodextrin (SBEbCD), and pharmaceutically acceptable salts thereof
• MflCD methyl beta-Cyclodextrin
• HI ⁇ CD 2-hydroxypropyl beta-Cyclodextrin
• SBEbCD sulfobutyl ether b-Cyclodextrin
• pharmaceutically acceptable salts thereof is administered 1-10 times a day, once a day, twice, three, four, or more times a day, 1-3 times a day, 2-4 times a day, 3-6 times a day, 4-8 times a day or 5-10 times a day.
• the substituted b- Cyclodextrin e.g., methyl beta-Cyclodextrin (MpCD), 2-hydroxypropyl beta-Cyclodextrin (HRbO ⁇ ), sulfobutyl ether b-Cyclodextrin (SBEbCD), and pharmaceutically acceptable salts thereof
• MpCD methyl beta-Cyclodextrin
• HRbO ⁇ 2-hydroxypropyl beta-Cyclodextrin
• SBEbCD sulfobutyl ether b-Cyclodextrin
• pharmaceutically acceptable salts thereof is administered every day, every other day, 2-3 times a week, or 3-6 times a week.
• the dose of the substituted b-Cyclodextrin can be, for example, in the range of about 0.01, 0.1, 0.5, 1, 5, 10, or 100 mg per kg of body weight per day to about 20, 50, 100, 500, or 1000 mg per kilogram of body weight. Particularly in
• the dosage administered can be independent of body weight, and can be in smaller amounts (e.g., 1-1000 pg per dose).
• Formulations of the present technology suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present technology as an active ingredient.
• the active compound may also be administered as a bolus, electuary, or paste.
• Methods of preparing these formulations generally include the step of admixing a b- cyclodextrin of the present technology or pharmaceutically acceptable salt thereof, with the carrier, and optionally, one or more auxiliary agents.
• a solid dosage form e.g., capsules, tablets, pills, powders, granules, trouches, and the like
• the active compound can be admixed with a finely divided solid carrier, and typically, shaped, such as by pelletizing, tableting, granulating, powderizing, or coating.
• the solid carrier may include, for example, sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as poloxamer and sodium lauryl sulfate; (7) wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non-ionic sur
• compositions may also comprise buffering agents.
• Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
• a tablet may be made by compression or molding, optionally with one or more auxiliary ingredients.
• Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface- active or dispersing agent.
• binder for example, gelatin or hydroxypropylmethyl cellulose
• lubricant for example, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface- active or dispersing agent.
• disintegrant for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose
• surface- active or dispersing agent for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose
• the tablets, and other solid dosage forms of the active agent such as capsules, pills and granules, may optionally be scored or prepared
• the dosage form may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
• the dosage form may alternatively be formulated for rapid release, .g..
• the dosage form is required to be sterile.
• the dosage form may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
• the pharmaceutical compositions may also contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
• the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
• Liquid dosage forms are typically a pharmaceutically acceptable emulsion, microemulsion, solution, suspension, syrup, or elixir of the active agent.
• the liquid dosage form may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
• inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers
• Dosage forms specifically intended for topical or transdermal administration can be in the form of, for example, a powder, spray, ointment, paste, cream, lotion, gel, solution, or patch. Ophthalmic formulations, such as eye ointments, powders, solutions, and the like, are also contemplated herein.
• the active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
• the topical or transdermal dosage form may contain, in addition to an active compound of this present technology, one or more excipients, such as those selected from animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, and mixtures thereof.
• Sprays may also contain customary propellants, such as
• chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons such as butane and propane.
• transdermal patches may provide the advantage of permitting controlled delivery of a compound of the present technology into the body.
• dosage forms can be made by dissolving or dispersing the compound in a suitable medium.
• Absorption enhancers can also be included to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
• compositions of this present technology suitable for parenteral administration generally include one or more compounds of the present technology in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders that may be reconstituted into sterile injectable solutions or dispersions prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, or solutes that render the formulation isotonic with the blood of the intended recipient.
• the absorption of the drug in order to prolong the effect of a drug, it may be desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
• Injectable depot forms can be made by forming microencapsule matrices of the active compound in a biodegradable polymer, such as polylactide-polyglycolide.
• the rate of drug release can be controlled.
• biodegradable polymers include poly(orthoesters) and poly(anhydrides).
• Depot injectable formulations can also be prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
• the pharmaceutical composition may also be in the form of a microemulsion.
• bioavailability of the active agent may be improved.
• the pharmaceutical composition may also contain micelles formed from a compound of the present technology and at least one amphiphilic carrier, in which the micelles have an average diameter of less than about 100 nm. In some embodiments, the micelles have an average diameter less than about 50 nm, or an average diameter less than about 30 nm, or an average diameter less than about 20 nm.
• amphiphilic carrier is generally one that has been granted Generally -Recognized-as- Safe (GRAS) status, and that can both solubilize the compound of the present technology and microemulsify it at a later stage when the solution comes into a contact with a complex water phase (such as one found in the living biological tissue).
• GRAS Generally -Recognized-as- Safe
• amphiphilic ingredients that satisfy these requirements have HLB (hydrophilic to lipophilic balance) values of 2-20, and their structures contain straight chain aliphatic radicals in the range of C-6 to C-20.
• HLB hydrophilic to lipophilic balance
• amphiphilic agents include polyethylene-glycolized fatty glycerides and polyethylene glycols.
• amphiphilic carriers are saturated and monounsaturated
• polyethyleneglycolyzed fatty acid glycerides such as those obtained from fully or partially hydrogenated various vegetable oils.
• oils may advantageously consist of tri-. di- and mono-fatty acid glycerides and di- and mono-polyethyleneglycol esters of the corresponding fatty acids, such as a fatty acid composition including capric acid 4-10, capric acid 3-9, lauric acid 40-50, myristic acid 14-24, palmitic acid 4-14 and stearic acid 5-15%.
• Another useful class of amphiphilic carriers includes partially esterified sorbitan and/or sorbitol, with saturated or mono-unsaturated fatty acids (SPAN-series) or corresponding ethoxylated analogs (TWEEN-series).
• amphiphilic carriers including the Gelucire®-series, Labrafil®, Labrasol®, or Lauroglycol®, PEG- mono-oleate, PEG-di-oleate, PEG-mono-laurate and di-laurate, Lecithin, Polysorbate 80.
• Elydrophilic polymers suitable for use in the pharmaceutical composition are generally those that are readily water-soluble, can be covalently attached to a vesicle-forming lipid, and that are tolerated in vivo without substantial toxic effects (i.e., are biocompatible).
• Suitable polymers include, for example, polyethylene glycol (PEG), polylactic (also termed polylactide), polyglycolic acid (also termed polyglycolide), a polylactic-polyglycolic acid copolymer, and polyvinyl alcohol.
• Exemplary polymers are those having a molecular weight of from about 100 or 120 daltons up to about 5,000 or 10,000 daltons, and more preferably from about 300 daltons to about 5,000 daltons.
• the polymer is polyethylene glycol having a molecular weight of from about 100 to about 5,000 daltons, or a molecular weight of from about 300 to about 5,000 daltons, or a molecular weight of 750 daltons, i.e., PEG(750). Polymers may also be defined by the number of monomers therein.
• the pharmaceutical compositions of the present technology utilize polymers of at least about three monomers, such PEG polymers comprising of at least three monomers, or approximately 150 daltons.
• Other hydrophilic polymers that may be suitable for use in the present technology include polyvinylpyrrolidone, polymethoxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide,
• the pharmaceutical composition includes a biocompatible polymer selected from polyamides, polycarbonates, polyalkylenes, polymers of acrylic and methacrylic esters, polyvinyl polymers, polyglycolides, polysiloxanes, polyurethanes and co-polymers thereof, celluloses, polypropylene, polyethylenes, polystyrene, polymers of lactic acid and glycolic acid, polyanhydrides, poly(ortho)esters, poly(butic acid), poly(valeric acid), poly(lactide-co-caprolactone), polysaccharides, proteins, polyhyaluronic acids, polycyanoacrylates, and blends, mixtures, and copolymers thereof.
• a biocompatible polymer selected from polyamides, polycarbonates, polyalkylenes, polymers of acrylic and methacrylic esters, polyvinyl polymers, polyglycolides, polysiloxanes, polyurethanes and co-polymers thereof, celluloses, polypropy
• the pharmaceutical composition may also be in liposomal form.
• Liposomes contain at least one lipid bilayer membrane enclosing an aqueous internal compartment. Liposomes may be characterized by membrane type and by size. Small unilamellar vesicles (SUVs) have a single membrane and typically range from 0.02 to 0.05 pm in diameter; large unilamellar vesicles (LUVS) are typically larger than 0.05 pm Oligolamellar large vesicles and multilamellar vesicles have multiple, usually concentric, membrane layers, and are typically larger than 0.1 pm.
• the liposomes may also contain several smaller vesicles contained within a larger vesicle, i.e., multivesicular vesicles.
• the pharmaceutical composition includes liposomes containing one or more b-cyclodextrins or pharmaceutically acceptable salts thereof of the present technology, where the liposome membrane is formulated to provide an increased carrying capacity.
• the one or more b-cyclodextrins or pharmaceutically acceptable salts of the present technology may be contained within, or adsorbed onto, the liposome bilayer of the liposome.
• the active agent may be aggregated with a lipid surfactant and carried within the liposome's internal space. In such cases, the liposome membrane is formulated to resist the disruptive effects of the active agent-surfactant aggregate.
• the lipid bilayer of a liposome contains lipids derivatized with polyethylene glycol (PEG), such that the PEG chains extend from the inner surface of the lipid bilayer into the interior space encapsulated by the liposome, and extend from the exterior of the lipid bilayer into the surrounding environment.
• PEG polyethylene glycol
• Active agents contained within liposomes are preferably in solubilized form. Aggregates of surfactant and active agent (such as emulsions or micelles containing the active agent of interest) may be entrapped within the interior space of liposomes.
• a surfactant typically serves to disperse and solubilize the active agent.
• the surfactant may be selected from any suitable aliphatic, cycloaliphatic or aromatic surfactant, including but not limited to biocompatible lysophosphatidylcholines (LPCs) of varying chain lengths, e.g., from about 14 to 20 carbons.
• Polymer-derivatized lipids such as PEG-lipids, may also be utilized for micelle formation as they will act to inhibit micelle/membrane fusion, and as the addition of a polymer to surfactant molecules decreases the critical micelle concentration (CMC) of the surfactant and aids in micelle formation.
• CMC critical micelle concentration
• Liposomes according to the present technology may be prepared by any of a variety of techniques known in the art, such as described in, for example, U.S. Pat. No.
• liposomes may be prepared by diffusing a lipid derivatized with a hydrophilic polymer into preformed liposomes, such as by exposing preformed liposomes to micelles composed of lipid-grafted polymers, at lipid concentrations corresponding to the final mole percent of derivatized lipid which is desired in the liposome.
• Liposomes containing a hydrophilic polymer can also be formed by homogenization, lipid-field hydration, or extrusion techniques, as are known in the art.
• the active agent is first dispersed by sonication in a
• micellar suspension of active agent is then used to rehydrate a dried lipid sample that contains a suitable mole percent of polymer-grafted lipid, or cholesterol.
• the lipid and active agent suspension is then formed into liposomes using extrusion techniques well known in the art, and the resulting liposomes separated from the unencapsulated solution by standard column separation.
• the liposomes are prepared to have substantially homogeneous sizes in a selected size range.
• One effective sizing method involves extruding an aqueous suspension of the liposomes through a series of polycarbonate membranes having a selected uniform pore size. The pore size of the membrane will correspond roughly with the largest sizes of liposomes produced by extrusion through the membrane (U.S. Pat. No. 4,737,323, the contents of which are herein incorporated by reference in their entirety).
• the release characteristics of a formulation of the present technology depend on several factors, including, for example, the type and thickness of the encapsulating material, the concentration of encapsulated drug, and the presence of release modifiers.
• the release can be manipulated to be pH dependent, such as by using a pH-sensitive coating that releases only at a low pH, as in the stomach, or releases at a higher pH, as in the intestine.
• An enteric coating can be used to prevent release from occurring until after passage through the stomach.
• Multiple coatings or mixtures of cyanamide encapsulated in different materials can be used to obtain an initial release in the stomach, followed by later release in the intestine.
• Release can also be manipulated by inclusion of salts or pore-forming agents, which can increase water uptake or release of drug by diffusion from the capsule. Excipients that modify the solubility of the drug can also be used to control the release rate. Agents that enhance degradation of the matrix or release from the matrix can also be incorporated. The agents can be added to the drug, added as a separate phase (i.e., as particulates), or can be co dissolved in the polymer phase depending on the compound. In all cases, the amount is preferably between 0.1 and thirty percent (w/w polymer). Some types of degradation enhancers include inorganic salts, such as ammonium sulfate and ammonium chloride;
• organic acids such as citric acid, benzoic acid, and ascorbic acid
• inorganic bases such as sodium carbonate, potassium carbonate, calcium carbonate, zinc carbonate, and zinc hydroxide
• organic bases such as protamine sulfate, spermine, choline, ethanolamine, diethanolamine, and triethanolamine
• surfactants such as a TweenTM or PluronicTM commercial surfactant.
• Pore-forming agents that add microstructure to the matrices i.e., water-soluble compounds, such as inorganic salts and sugars
• water-soluble compounds such as inorganic salts and sugars
• Uptake can also be manipulated by altering residence time of the particles in the body. This can be achieved by, for example, coating the particle with, or selecting as the encapsulating material, a mucosal adhesive polymer.
• a mucosal adhesive polymer examples include most polymers with free carboxyl groups, such as chitosan, celluloses, and especially polyacrylates (as used herein, polyacrylates refers to polymers including acrylate groups and modified acrylate groups such as cyanoacrylates and methacrylates).
• the examples should in no way be construed as limiting the scope of the present technology, as defined by the appended claims.
• the examples can include or incorporate any of the variations, aspects, or embodiments of the present technology described above.
• the variations, aspects, or embodiments described above may also further each include or incorporate the variations of any or all other variations, aspects or embodiments of the present technology.
• LBs are auto-fluorescent molecules on account of the abundant conjugated double bonds in their hydrophobic arms. When excited at 430 nm (blue light) they emit yellow-orange fluorescence peaking at 610 nm. The intensity of the fluorescence is proportional to their amounts. Hoechst blue fluorescence dye was used to stain the nucleus of cells treated with cyclodextrins. In this way, one is able to express the 610 nm emission peak (amount of LBs) in relationship to the number of cells in the imaged field. Each dose was assayed in triplicated and ten random fields were evaluated per well.
• Fluorescence plate reader method Methyl b-Cyclodextrins reduce lipid bisretinoids (LB) content, in vitro and in vivo, using fluorescence microscopy and HPLC (Nociari et al ., Proc Natl Acad Sci USA. 111(14): E1402-E1408 (2014)).
• these methods lack sufficient linearity and sensitivity to provide robust and unbiased assessment of LB quantities.
• a simple and sensitive microplate assay was developed to quantify LB removal. Briefly, the conditions to preload a confluent culture of RPE cells with non-toxic doses of A2E (5 mM) were optimized.
• the cells were preloaded with low doses of A2E in one or repetitive steps, at least one week before the assay. These cells may be kept loaded for months until needed for a removal assay. 48 hours before an assay, cells were then trypsinized, counted and seeded in 96 well glass bottom plates at a density of 1 c 10 5 cells per well. After 48 hrs, cells were treated O/N (at least in
• A2E-extraction buffer contains a mix of 2% Triton X-100 and 1% SDS in PBS. Triton- 100 is known to form complexes with b Cyclodextrins at higher affinity than A2E. At 2% Triton, there is a great excess of detergent respect any amount of A2E that could be potentially be released from the loaded cells.
• CD cyclodextrins
• Figures 4A-4B show fluorescence of A2E inside the cells (unextracted cells) monitored by fluorescence microscopy with a 100X magnification objective after staining with Hoechst dye for 1 hour to visualize nuclei.
• Top panel shows LB-rich lipofuscin accumulation in an untreated control (A2E-Untreated).
• the untreated cells showed both blue DNA fluorescence, and yellow punctate LB fluorescence, in the cytoplasm. This localization was consistent with previously reported localization inside the lysosomes.
• Bottom panel shows that LB was expelled outside the cells after the treatment with methyl b-Cyclodextrin. Indeed, extracellular release of granules of A2E appeared to be induced by the treatment.
• l x lO 5 A2E-loaded and control cells per well were cultured in serum free media and after 4 hrs treatment with 12.5 mM Methyl b-Cyclodextrin (MBCD); Hydroxy propyl b-Cyclodextrin (HPBCD); or Sulfo Butyl Ether b-Cyclodextrin (SBE-BCD).
• MCD Methyl b-Cyclodextrin
• HPBCD Hydroxy propyl b-Cyclodextrin
• SBE-BCD Sulfo Butyl Ether b-Cyclodextrin
• Adherent cells were lysed in IX A2E extraction buffer and supernatants were transferred to a fresh set of wells where concentrated A2E extraction buffer was added to obtain a IX final concentration, thus allowing quantification of A2E secreted into the media. As shown in Figure 7, all A2E fluorescence that was absent from cells was present in supernatants.
• methyl b-Cyclodextrin To determine the effective doses of methyl b-Cyclodextrin, epithelial cells loaded with A2E were incubated with increasing doses of methyl b-Cyclodextrin. After incubation for 24 hrs, methyl b-Cyclodextrin was removed from the cells and the amount of A2E still associated with the cells was determined. As shown in Figure 3A, the effects of methyl b- Cyclodextrin on the removal of A2E was dose-dependent. The lowest tested dose showed about 75% removal, compared to untreated control. Doses as low as 10-20 mM methyl b- Cyclodextrin removed most of the detectable LB deposits from the epithelial cells.
• MCD Methyl b-Cyclodextrin
• HPBCD Hydroxy propyl b-Cyclodextrin
• SBE-BCD Sulfo Butyl Ether b-Cyclodextrin
• Biol Chem 283(39):26684-93) were treated with two intravitreal injections of 2 m ⁇ lOOmM Mbq ⁇ ; 1 m ⁇ 500hiM HRbO ⁇ ; or 1 m ⁇ 500mM SBE- bq ⁇ and left eyes (OS) were mock-treated with vehicle alone.
• a separate group of age matched control animals was also treated with vehicle alone to stablish the baseline autofluorescence in the eyes of these mice.
• the second identical injection was administered a week later. Eyes were harvested 4 days after the second injection and retinal pigment epithelium (RPE)-eyecups were flat mounted.
• RPE retinal pigment epithelium
• SF Spatial Frequency response
• OMT OptoMotry
• a range includes each individual member.
• a group having 1-3 cells refers to groups having 1, 2, or 3 cells.
• a group having 1-5 cells refers to groups having 1, 2, 3, 4, or 5 cells, and so forth.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Polymers & Plastics (AREA)
• Ophthalmology & Optometry (AREA)
• General Chemical & Material Sciences (AREA)
• Biochemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Materials Engineering (AREA)
• Inorganic Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)

Priority Applications (15)

Applications Claiming Priority (2)

Publications (1)

Family

ID=72337111

Family Applications (1)

Country Status (16)

Cited By (2)

Families Citing this family (2)

Citations (2)

Family Cites Families (8)

• 2020
  • 2020-03-03 AU AU2020232266A patent/AU2020232266A1/en not_active Abandoned
  • 2020-03-03 US US17/436,023 patent/US20220118002A1/en active Pending
  • 2020-03-03 WO PCT/US2020/020805 patent/WO2020180872A1/en not_active Ceased
  • 2020-03-03 BR BR112021017529A patent/BR112021017529A2/pt not_active Application Discontinuation
  • 2020-03-03 EP EP20767194.2A patent/EP3934660A4/en active Pending
  • 2020-03-03 JP JP2021552728A patent/JP7573881B2/ja active Active
  • 2020-03-03 EA EA202192183A patent/EA202192183A1/ru unknown
  • 2020-03-03 PH PH1/2021/552131A patent/PH12021552131A1/en unknown
  • 2020-03-03 KR KR1020217031603A patent/KR20210142651A/ko not_active Ceased
  • 2020-03-03 CN CN202080031946.8A patent/CN113747902A/zh active Pending
  • 2020-03-03 CA CA3132466A patent/CA3132466A1/en active Pending
  • 2020-03-03 MX MX2021010650A patent/MX2021010650A/es unknown
  • 2020-03-03 SG SG11202109541YA patent/SG11202109541YA/en unknown
• 2021
  • 2021-08-31 IL IL286002A patent/IL286002A/en unknown
  • 2021-09-07 ZA ZA2021/06559A patent/ZA202106559B/en unknown
  • 2021-09-20 CO CONC2021/0012267A patent/CO2021012267A2/es unknown

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events